A Phase 2/3, Prospective, Open-label Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Remimazolam for Intravenous Sedation in Paediatric Patients Undergoing Diagnostic and/or Therapeutic Procedures
Latest Information Update: 12 Sep 2023
At a glance
- Drugs Remimazolam (Primary)
- Indications Sedation
- Focus Registrational; Therapeutic Use
- Sponsors Acacia Pharma; PAION
- 30 Jan 2023 This trial has been suspended in Denmark, according to European Clinical Trials Database.
- 12 Dec 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 12 Dec 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.